Citadel & Centurion are multi-center studies that are evaluating the use of TYRX’s AIGISRx Antibacterial Envelope in patients who are at high risk for cardiovascular implantable electronic devices infection. High-risk patients are those whose current CIED is being replaced with an implantable cardioverter-defibrillator or a cardiac resynchronization therapy device accompanied by the AIGISRx.
The AIGISRx Antibacterial Envelope is a mesh device that holds a pacemaker or implantable cardioverter-defibrillator in place and is coated with antibiotic agents to reduce infections.
More Articles on TYRX:
Study Reveals TYRX Antibacterial Envelope Helps Lower Infections From Cardiac Devices
TYRX Announces ICD-9 Code for AIGISRx Antibacterial Envelope
TYRX Launches New Patient Education Website
